Despite all of the scrutiny and anger directed at Mylan, the maker of the EpiPen allergy treatment, the company’s CEO will not say firmly that the price of the drug will be lowered after increasing by about 500% in less than a decade. When asked about the matter, Mylan CEO Heather Bresch told CNBC only that she would be looking forward to working with Washington to find solutions for problems in the US healthcare system. Not really an answer, you may notice.
0 thoughts on “Here’s Why it’s Ridiculously Tempting for the CEO of Mylan to Keep Hiking the EpiPen Price”
Comments are closed.